Sanjit Bardhan to Lead Salient Systems International Sales in the Middle East, Africa, and India
9.1.2020 21:47:00 EET | Business Wire | Press release
Salient Systems Corporation, a leader in enterprise video surveillance management solutions, is pleased to announce Sanjit Bardhan has been appointed as Director of Middle East, Africa, and India. Mr. Bardhan will report to Ethan Maxon, Vice President - International Sales, at Salient Systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200109005764/en/
Sanjit Bardhan, Director of Middle East, Africa, and India, Salient Systems (Photo: Business Wire)
Mr. Sanjit Bardhan is an accomplished, proven and highly motivated global sales leader with demonstrated success growing and transforming businesses through strong client relationships, employee motivation, collaboration and initiative.
In addition, Mr. Bardhan’s experience encompasses many successful years as Vice President, International Sales for Arecont Vision Costar and served as a member of the Executive Management Team. Prior to his time at Arecont Vision Costar, Mr. Bardhan was part of successful sales teams at both Anixter International and Schneider Electric. He brings invaluable experience to Salient Systems as the company expands its sales, marketing and operational influence internationally.
In his new role, Mr. Bardhan will be part of the corporate team that designs and deploys large, complex security management systems sales in strategic accounts, including global deployment standards while maintaining a single point of contact for both the systems integrator partner and project rollout. His leadership will position Salient Systems in the forefront of the physical security industry, implement strategies for strategic international growth, and support the corporate objectives for revenue and profitability.
Mr. Bardhan will be based in Dubai, United Arab Emirates, where he will also be leading Salient’s efforts to open an office.
“Over my years in international business, Sanjit Bardhan has proven to be the single strongest talent I have ever worked with,” says Ethan Maxon. “While at Arecont Vision, he progressed from Regional Manager for the Middle East to Vice President, International, involving 4 separate promotions over 8 years. More importantly Sanjit is a unique blend of talent for sales leadership, sales growth, and ethical business practices. We are excited to have Sanjit as part of the Salient Team!”
About Salient
Salient Systems offers comprehensive, enterprise video surveillance systems designed for the full range of surveillance technology needs from analog to IP to Cloud. Based on open architecture, CompleteView 2020 scales from entry level to enterprise and provides everything needed to manage a multi-server, multi-site video surveillance installation from a desktop, laptop or mobile device.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005764/en/
Contact information
Mary Wilbur
mary.wilbur@salientsys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom